Avalo Therapeutics, Inc. AVTX
6.75 USD +0.05 (+0.75%)
Regular-session close
6.75 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
6.53 Day range 6.87
6.53 52-week range 24.27
- YTD
- -62.83%
- 1 year
- -61.63%
Revenue & Expenses
Revenue Profit Costs
Latest period ending Dec 31, 2025 · select a line to chart its full history
Income statement
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 59.00K | 441.00K | 1.92M | 18.05M | 5.40M | |
| 59.00K | 807.00K | 640.00K | 14.62M | 3.91M | |
| -72.92M | -68.51M | -27.35M | -37.44M | -82.13M | |
| -78.26M | -35.13M | -31.54M | -41.66M | -84.38M | |
| -5.84 | -20.91 | -113.58 | -1,063.00 | -2,388.00 |
Balance sheet
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 15.89M | 134.56M | 7.42M | 13.19M | 54.64M | |
| 116.46M | 150.73M | 20.99M | 33.37M | 80.21M | |
| 33.41M | 17.70M | 13.69M | 44.28M | 57.13M | |
| 83.05M | 133.03M | 7.30M | -10.91M | 23.08M |
Cash flow
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| -51.46M | -49.06M | -30.68M | -26.75M | -70.89M | |
| -81.72M | 356.00K | -133.00K | -95.00K | -113.00K | |
| 14.59M | 175.85M | 25.04M | -14.70M | 106.76M | |
| -118.59M | 127.15M | -5.77M | -41.55M | 35.76M |
